Citations

Clear

4847 citation(s) found for "Yu, Eric".

A Combination of a Polycaprolactone Fumarate Scaffold with Polyethylene Terephthalate Sutures for Intra-Articular Ligament Regeneration
Parry, Joshua A. , Wagner, Eric R. , Kok, Peter L., Dadsetan, Mahrokh, Yaszemski, Michael J. , Wijnen, André J. van , van Wijnen, Andre J, Kakar, Sanjeev , van Wijnen, Andre J , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | May 20, 2017 | Volume: 24 | Issue: 3-4 | Pages: 245-253

10.1089/ten.tea.2016.0531 | PMID 28530131 Get It

“Snare-Ride”: A Bailout Technique to Catheterize Target Vessels With Unfriendly Anatomy in Branched Endovascular Aortic Repair
Ferreira, Marcelo , Katsargyris, Αthanasios , Rodrigues, Eduardo, Ferreira, Diego, Cunha, Rodrigo, Bicalho, Guilherme , Oderich, Gustavo S. , Verhoeven, Eric L.G. , Oderich, Gustavo, Rodrigues, Eduardo, Oderich, Gustavo S.

Mayo Clinic

Journal of Endovascular Therapy | May 18, 2017 | Volume: 24 | Issue: 4 | Pages: 556-558

10.1177/1526602817709465 | PMID 28514896 Get It

Purpose: To describe a novel endovascular bailout technique for successful completion of target vessel stenting during branched stent-graft repair of thoracoabdominal aortic aneurysms (TAAA) after encountering difficulties with standard catheterization techniques. Technique: Technical difficulties when using fenestrated and branched grafts should be expected, especially in difficult anatomy or when an off-the-shelf device (eg, standard 4-branch device) is used that does not perfectly “match” the anatomy. The “snare-ride technique” facilitates antegrade transaxillary side branch catheterization and stent placement during TAAA branched grafting using a snare via a transfemoral approach. The branch of the graft is catheterized from an axillary access. The respective target vessel is then catheterized via a femoral access. An Indy snare is advanced over the transfemoral wire and positioned near the entrance of the target vessel. The transaxillary wire inside the branch of the graft is then advanced, snared, and pushed inside the target vessel with the snare. The procedure is thereafter continued with antegrade bridging of the target vessel in routine fashion. Conclusion: The snare-ride technique can be a useful maneuver to catheterize target vessels with difficult anatomy in TAAA branched stent-graft repair. Early experience shows safety and feasibility.
Development of a Unifying Target and Consensus Indicators for Global Surgical Systems Strengthening: Proposed by the Global Alliance for Surgery, Obstetric, Trauma, and Anaesthesia Care (The G4 Alliance)
Haider, Adil H. , Scott, John W. , Gause, Colin D., Meheš, Mira, Hsiung, Grace, Prelvukaj, Albulena, Yanocha, Dana, Baumann, Lauren M., Ahmed, Faheem , Ahmed, Naeem , Anderson, Sara, Angaté, Hervé, Arfaa, Lisa, Asbun, Horacio J. , Ashengo, Tigistu Adamu , Asuman, Kisembo, Ayala, Ruben , Bickler, Stephen W. , Billingsley, Saul, Bird, Peter, Botman, Matthijs , Butler, Marilyn, Buyske, Jo, Capozzi, Angelo, Casey, Kathleen , Clayton, Charles, Cobey, James C., Cotton, Michael , Deckelbaum, Dan, Derbew, Miliard , deVries, Catherine R. , Dillner, Jeanne, Downham, Max, Draisin, Natalie, Echinard, David, Elneil, Sohier , ElSayed, Ahmed , Estelle, Abigail, Finley, G. Allen , Frenkel, Erica, Frykman, Philip K., Gheorghe, Florin, Gore‐Booth, Julian, Henker, Richard , Henry, Jaymie , Henry, Orion, Hoemeke, Laura , Ibanga, Iko, Jackson, Eric V., Jani, Pankaj , Johnson, Walter D. , Jones, Andrew , Kassem, Zeina, Kocan, Abbey, Krishnaswami, Sanjay , Lane, Robert H. , Latif, Asad , Levy, Barbara , Linos, Dimitrios , Linz, Peter E., Listwa, Louis A., Magee, Declan, Makasa, Emmanuel , Marin, Michael L. , Martin, Claude , McQueen, Kelly, Morgan, Jamie , Moser, Richard , Neighbor, Robert, Novick, William M. , Ogendo, Stephen, Omigbodun, Akinyinka , Onajin‐Obembe, Bisola , Parsan, Neil, Philip, Beverly K., Price, Raymond R. , Rasheed, Shahnawaz, Ratel, M, Reynolds, Cheri, Roser, Steven M. , Rowles, Jackie , Samad, Lubna , Sampson, John , Sanghvi, Harshadkumar, Sellers, Marchelle L., Sigalet, David L. , Steffes, Bruce C., Stieber, Erin, Swaroop, Mamta , Tarpley, John L. , Varghese, Asha , Varughese, Julie, Wagner, Richard, Warf, Benjamin C. , Wetzig, Neil , Williamson, Susan , Wood, Joshua, Zeidan, Anne, Zirkle, Lewis G. , Allen, Brendan, Abdullah, Fizan , Asbun, Horacio, Butler, Marilyn, Gheorghe, Florin, Hoffman, David C. , Lane, Robert, Varughese, Julie

Mayo Clinic

World Journal of Surgery | May 15, 2017 | Volume: 41 | Issue: 10 | Pages: 2426-2434

10.1007/s00268-017-4028-1 | PMID 28508237 Get It

AbstractAfter decades on the margins of primary health care, surgical and anaesthesia care is gaining increasing priority within the global development arena. The 2015 publications of the Disease Control Priorities third edition on Essential Surgery and the Lancet Commission on Global Surgery created a compelling evidenced‐based argument for the fundamental role of surgery and anaesthesia within cost‐effective health systems strengthening global strategy. The launch of the Global Alliance for Surgical, Obstetric, Trauma, and Anaesthesia Care in 2015 has further coordinated efforts to build priority for surgical care and anaesthesia. These combined efforts culminated in the approval of a World Health Assembly resolution recognizing the role of surgical care and anaesthesia as part of universal health coverage. Momentum gained from these milestones highlights the need to identify consensus goals, targets and indicators to guide policy implementation and track progress at the national level. Through an open consultative process that incorporated input from stakeholders from around the globe, a global target calling for safe surgical and anaesthesia care for 80% of the world by 2030 was proposed. In order to achieve this target, we also propose 15 consensus indicators that build on existing surgical systems metrics and expand the ability to prioritize surgical systems strengthening around the world.
Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism
Savica, Rodolfo , Bower, James H., Ahlskog, J. Eric , Graff‐Radford, Jonathan , Rocca, Walter A. , Grossardt, Brandon R. , Boeve, Bradley F. , Mielke, Michelle M.

Mayo Clinic

JAMA Neurology | May 15, 2017 | Volume: 74 | Issue: 7 | Pages: 839

10.1001/jamaneurol.2017.0603 | PMID 28505261 Get It

A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Goss, Paul E. , Robert, Nicholas J. , Muss, Hyman B. , Whelan, Timothy J. , Strasser‐Weippl, Kathrin , Rubin, S., Sturtz, Keren , Hudis, Clifford A. , Kaur, Judith S. , Whelan, Kate, Parulekar, Wendy R. , Ingle, James N. , Pritchard, Kathleen I. , Gralow, Julie R. , Gelmon, Karen A. , Wolff, Antonio C. , Winer, Eric P. , Stopeck, Alison , Beck, J. Thaddeus , Tu, Dongsheng , Whelan, Timothy J

Mayo Clinic

Journal of Clinical Oncology | May 11, 2017 | Volume: 34 | Issue: 18_suppl | Pages: LBA1-LBA1

10.1200/jco.2016.34.18_suppl.lba1 Get It

LBA1 Background: Five years of aromatase inhibitor (AI) therapy either as up-front treatment or after 2-5 years of tamoxifen has become the standard of care for postmenopausal women with hormone receptor positive early breast cancer. Extending treatment with an AI to 10 years may further reduce the risk of breast cancer recurrence. Methods: We conducted a double-blind, placebo-controlled trial (Canadian Cancer Trials Group MA.17R) to test the efficacy of extending AI treatment for an additional five years using letrozole. The primary endpoint was disease-free survival. Results: A total of 1,918 women with early stage breast cancer were enrolled (median follow-up 75 months, 6.3 years). A total of 165 disease-free survival (DFS) events (67 on letrozole and 98 on placebo) occurred, of which 42 versus 53 were distant recurrences on letrozole and placebo, respectively. There were 200 deaths (100 in each treatment group). The 5 year DFS was respectively 95% for patients receiving letrozole versus 91% for those on placebo (HR 0.66; P = 0.01) from a two-sided log-rank test stratified by nodal status, prior adjuvant chemotherapy, interval between last dose of AI therapy and randomization, and duration of prior tamoxifen at randomization. The 5 year overall survival was respectively 93% for subjects on letrozole and 94% on placebo with a HR of 0.97 (P = 0.83). The annual incidence rate of contralateral breast cancer was 0.21% for subjects on letrozole versus 0.49% on placebo (P = 0.007). Conclusions: Compared to 5 years of AI treatment as initial therapy or preceded by 2-5 years of tamoxifen, extending AI treatment to 10 years significantly improves disease-free survival. Further analyses will provide a comprehensive picture of toxicities and QOL. Clinical trial information: NCT00754845.
Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses
Bào, Yīmíng , Basler, Christopher F. , Bavari, Sina , Bukreyev, Alexander , Chandran, Kartik , Dolnik, Olga , Dye, John M. , Ebihara, Hideki , Formenty, Pierre , Hewson, Roger , Kobinger, Gary , Leroy, Eric M. , Mühlberger, Elke , Sv, Netesov , Patterson, Jean L. , Smither, Sophie J. , Takada, Ayato , Volchkov, Viktor E. , Wahl‐Jensen, Victoria , Kuhn, Jens H. , Amarasinghe, Gaya K. , Paweska, Janusz Tadeusz , Towner, Jonathan S. , Ebihara, Hideki , Mühlberger, Elke

Mayo Clinic

Viruses | May 11, 2017 | Volume: 9 | Issue: 5 | Pages: 106

10.3390/v9050106 | PMID 28492506 Get It

The mononegaviral family Filoviridae has eight members assigned to three genera and seven species. Until now, genus and species demarcation were based on arbitrarily chosen filovirus genome sequence divergence values (≈50% for genera, ≈30% for species) and arbitrarily chosen phenotypic virus or virion characteristics. Here we report filovirus genome sequence-based taxon demarcation criteria using the publicly accessible PAirwise Sequencing Comparison (PASC) tool of the US National Center for Biotechnology Information (Bethesda, MD, USA). Comparison of all available filovirus genomes in GenBank using PASC revealed optimal genus demarcation at the 55–58% sequence diversity threshold range for genera and at the 23–36% sequence diversity threshold range for species. Because these thresholds do not change the current official filovirus classification, these values are now implemented as filovirus taxon demarcation criteria that may solely be used for filovirus classification in case additional data are absent. A near-complete, coding-complete, or complete filovirus genome sequence will now be required to allow official classification of any novel “filovirus.” Classification of filoviruses into existing taxa or determining the need for novel taxa is now straightforward and could even become automated using a presented algorithm/flowchart rooted in RefSeq (type) sequences.
Clinical Reasoning: A 45-year-old man with weakness and myalgia after orthopedic surgery
Campo, Rocio Vazquez Do , Siegel, Jason , Dimberg, Elliot L., Vazquez do Campo, Rocio, Dimberg, Elliot, Goldstein, Eric , Vazquez Do Campo, Rocio

Mayo Clinic

Neurology | May 8, 2017 | Volume: 88 | Issue: 19 | Pages: No page available

10.1212/wnl.0000000000003914 | PMID 28483995 Get It

Comparison of the hospital costs for two-stage reimplantation for deep infection, single-stage revision and primary total elbow arthroplasty
Wagner, Eric R. , Ransom, Jeanine E. , Kremers, Hilal Maradit , Morrey, Mark, Sanchez-Sotelo, Joaquin, Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Wagner, Eric R , Maradit Kremers, Hilal

Mayo Clinic

Shoulder & Elbow | May 8, 2017 | Volume: 9 | Issue: 4 | Pages: 279-284

10.1177/1758573217706364 | PMID 28932285 Get It

Background The purpose of the present study was to determine the cost of two-stage reimplantation for the treatment of deep infection after total elbow arthroplasty (TEA) and compare this with primary and aseptic revision TEA. Methods Three hundred and seventy-one primary TEA and 286 revision TEAs (including 47 elbows requiring two-stage reimplantation) were performed. Total direct medical costs during each hospitalization were obtained from our institutional research database and compared for three groups: primary TEA, revision for nonseptic reasons and two-stage reimplantation for deep infection. Results The mean cost of an uncomplicated primary TEA and aseptic revision TEA was $18,464 and $18,796, respectively. The mean overall cost associated with two-stage reimplantation increased to $34,286. Two-stage reimplantation increased both Part A (hospital costs) and Part B (professional costs). The mean Part A cost for septic revision TEA was $29,102 versus $15,844 for primary TEA. The mean Part B cost for septic revision TEA was $5,184 versus $2,621 for primary TEA. Conclusions Two-stage reimplantation for treatment of an infected TEA costs 186% the hospital cost of a primary uncomplicated or aseptic revision TEA. The overall cost to society is even greater if we take into account the cost of antibiotic therapy in between stages and lost days from work.
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Ho, Yeung, Etten, Jamie L. Van, Yang, Rendong , Li, Yingming , Tseng, Elizabeth , Hon, Ting, Clark, Tyson A. , Tan, Winston , Carlson, Rachel E. , Wang, Liguo , Sicotte, Hugues , Ho, Thai H. , Jiménez, Rafael E. , Vedell, Peter T. , Eckloff, Bruce W., Quevedo, J. Fernando , Pitot, Henry C., Costello, Brian A. , Jen, Jin , Wieben, Eric D. , Silverstein, Kevin A.T. , Wang, Liewei , Dehm, Scott M. , Kohli, Manish , Thai, Ho, Jimenez, Rafael, Quevedo, Jorge F, Hillman, David W. , Henzler, Christine M. , Sperger, Jamie M. , Huang, Haojie , Lang, Joshua M. , Ho, Thai , Wang, Liguo , Dehm, Scott M

Mayo Clinic

Clinical Cancer Research | May 4, 2017 | Volume: 23 | Issue: 16 | Pages: 4704-4715

10.1158/1078-0432.ccr-17-0017 | PMID 28473535 Get It

Abstract Purpose: Androgen receptor (AR) variant AR-V7 is a ligand-independent transcription factor that promotes prostate cancer resistance to AR-targeted therapies. Accordingly, efforts are under way to develop strategies for monitoring and inhibiting AR-V7 in castration-resistant prostate cancer (CRPC). The purpose of this study was to understand whether other AR variants may be coexpressed with AR-V7 and promote resistance to AR-targeted therapies. Experimental Design: We utilized complementary short- and long-read sequencing of intact AR mRNA isoforms to characterize AR expression in CRPC models. Coexpression of AR-V7 and AR-V9 mRNA in CRPC metastases and circulating tumor cells was assessed by RNA-seq and RT-PCR, respectively. Expression of AR-V9 protein in CRPC models was evaluated with polyclonal antisera. Multivariate analysis was performed to test whether AR variant mRNA expression in metastatic tissues was associated with a 12-week progression-free survival endpoint in a prospective clinical trial of 78 CRPC-stage patients initiating therapy with the androgen synthesis inhibitor, abiraterone acetate. Results: AR-V9 was frequently coexpressed with AR-V7. Both AR variant species were found to share a common 3′ terminal cryptic exon, which rendered AR-V9 susceptible to experimental manipulations that were previously thought to target AR-V7 uniquely. AR-V9 promoted ligand-independent growth of prostate cancer cells. High AR-V9 mRNA expression in CRPC metastases was predictive of primary resistance to abiraterone acetate (HR = 4.0; 95% confidence interval, 1.31–12.2; P = 0.02). Conclusions: AR-V9 may be an important component of therapeutic resistance in CRPC. Clin Cancer Res; 23(16); 4704–15. ©2017 AACR.